Small healthy-volunteer studies
Two linked reports found sustained GH and IGF-1 responses after CJC-1295. The sample sizes were small, the setting was controlled and the endpoints were biochemical. [1] [2]
Compound evidence dossier · C-015
CJC-1295: growth-hormone claims and endocrine risk
A GHRH analogue sold under more than one chemical identity. The human studies show hormone changes, while the outcomes advertised by sellers remain unproven.
What does the evidence say?
CJC-1295 can raise growth hormone and IGF-1 in small studies of healthy adults, but that is not proof of muscle gain, fat loss, recovery or anti-ageing benefit. “CJC-1295” is also used for products with and without a drug-affinity-complex group, even though those forms have different structures and persistence. A label that omits the form leaves a basic identity question unanswered.
Claim check
Which claims survive an evidence check?
Each row keeps the claim, its best supporting evidence and the limiting caveat together.
Raises growth hormone for daysPartly supported
A long-acting form produced sustained changes in growth hormone and IGF-1 in small studies of healthy adults. The papers measured hormone response, not recovery, body composition or long-term clinical benefit. The studied material appears to have been the DAC form, while descriptions of the exact salt were incomplete.
Builds muscle or reduces fatNot demonstrated
No reliable human outcome evidence establishes muscle gain or fat loss for the products now sold as CJC-1295. A rise in a biomarker cannot stand in for a patient-centred or performance outcome.
DAC and non-DAC are interchangeableFalse equivalence
The DAC attachment changes the molecule and its persistence. The FDA review found multiple nominated substances and inconsistent naming. Evidence for one form should not be transferred to another without a defensible identity match.
A clean COA proves the product is safeNot supported
A chromatogram may support identity or purity for the submitted sample. It does not prove sterility, dose accuracy, storage stability, biological effect or the contents of another vial.
Human evidence
What have studies in people shown?
The direct human evidence is pharmacodynamic: it asks whether a defined investigational material changes circulating hormones. It does not answer the commercial questions most buyers are asking.
Advertised outcomes
The studies did not establish better recovery, increased muscle, reduced fat, improved sleep or longer life. Those are separate claims requiring separate trials.
Identity and safety uncertainty
The FDA distinguished several nominated forms, found limited clinical data and described serious adverse events including increased heart rate and a systemic vasodilatory reaction. [3] [4]
Critical distinction
Why “with DAC” and “without DAC” cannot share one evidence file
The DAC group is not a branding detail. It changes the active moiety and expected pharmacokinetics, so a product labelled only “CJC-1295” is underspecified.
- With DAC
- The investigational long-acting conjugate studied in the published healthy-adult pharmacology papers.
- Without DAC
- A shorter-acting material often marketed under the same name; it should not inherit the DAC evidence by shorthand.
- What a label should settle
- Full peptide name, sequence or defensible identifier, salt or counter-ion where relevant, and whether the DAC group is present.
- What testing may settle
- Identity and purity for a submitted sample, if the method and reference material are fit for purpose. Persistence in a person is not a vial-test result.
Risk register
What could go wrong?
The direct human safety dataset is too small for reassurance. Endocrine stimulation, product ambiguity and injectable-product quality create separate risk channels.
| Risk channel | Evidence-aware interpretation |
|---|---|
| Direct clinical observations | Increased heart rate and a systemic vasodilatory reaction appear in the FDA safety summary. Frequency and long-term risk are not established. |
| Mechanism-linked concerns | Sustained GH and IGF-1 signalling can affect glucose regulation and fluid balance. The exact risk for unapproved CJC-1295 products is not quantified. |
| Product risk | Aggregation, peptide-related impurities, incorrect active moiety, dose error and non-sterility are not ruled out by a seller’s generic purity figure. |
| Unknowns | Repeated-use safety, interactions, vulnerable populations, cancer-related outcomes and risk by chemical form remain unresolved. |
Product evidence
What would evidence about a vial prove?
A compound-level literature verdict and a product-level finding answer different questions. Neither can substitute for the other.
Claimed compound
The literature applies only if the vial contains the same active substance and form that the source studied.
Label and release record
A batch-specific record should identify the material, method, result, specification and accountable laboratory.
Submitted sample
A defensible result concerns the sample tested. It does not certify every vial, future batch or storage condition.
Clinical meaning
Identity, purity and sterility evidence cannot establish a health outcome or fill a missing human safety dataset.
Status check
Is it authorised or prohibited?
Medicine authorisation, lawful supply and anti-doping status are separate checks. Each can change and should be verified at the point of decision.
| System | Finding checked 8 August 2026 |
|---|---|
| UK medicine status | No CJC-1295 medicine with a UK marketing authorisation was identified in the MHRA public database check. This is a regulatory observation, not a product-specific legal opinion. |
| United States | No form reviewed by the FDA was a component of an FDA-approved drug. The agency’s compounding review identified characterisation and safety concerns. |
| Sport | CJC-1295 is named within the growth-hormone-releasing-factor class on the 2026 WADA Prohibited List and is prohibited at all times. Athletes should check Global DRO and their anti-doping organisation. |
Method note
How was this judgement made?
We matched the healthy-volunteer papers to the regulator’s substance-identity review before carrying any finding across. Hormone endpoints were kept separate from body-composition and performance claims.
Searches prioritised regulator documents, current medicine and anti-doping records, trial registrations and indexed primary studies. Seller pages were not used as evidence of efficacy or safety.
Read the full editorial method and inspect the evidence library.
Source ledger
Primary sources
- Teichman et al., human pharmacokinetics and pharmacodynamics of CJC-1295Small healthy-adult study; biochemical endpoints. Checked 8 August 2026.
- Ionescu and Frohman, pulsatile GH secretion after CJC-1295Human physiology study; no consumer outcome endpoint. Checked 8 August 2026.
- US FDA, CJC-1295 Pharmacy Compounding Advisory Committee briefingSubstance identities, pharmacology, evidence gaps and regulatory assessment. Checked 8 August 2026.
- US FDA, Certain Bulk Drug Substances That May Present Significant Safety RisksCurrent regulator summary of characterisation, impurity, immunogenicity and safety concerns. Checked 8 August 2026.
- World Anti-Doping Agency, 2026 Prohibited ListCurrent list used for sport-status checks; effective 1 January 2026. Checked 8 August 2026.
- MHRA ProductsPublic UK medicines database used for the marketing-authorisation check. Checked 8 August 2026.
Questions answered
Frequently asked questions
Short answers keep the decisive caveat beside the claim.
Is CJC-1295 a medicine in the UK?
No UK-authorised CJC-1295 medicine was identified in the MHRA public database check. Products offered online should not be treated as authorised medicines on the strength of a peptide name or laboratory document.
What does DAC mean in CJC-1295?
DAC means drug affinity complex. It is an added chemical group designed to bind albumin and extend persistence. Its presence changes the active substance, so “with DAC” and “without DAC” should not share one evidence claim.
Does CJC-1295 increase growth hormone?
A long-acting CJC-1295 material increased GH and IGF-1 in small healthy-adult studies. That shows a hormone response under study conditions. It does not establish muscle growth, fat loss, recovery or long-term safety.
Can a COA prove which CJC-1295 variant is in a vial?
A suitable identity method may distinguish defined substances if the laboratory has the right reference material and reports the method in full. A generic purity percentage cannot settle variant identity by itself.
Is CJC-1295 prohibited in sport?
Yes. The 2026 WADA list names CJC-1295 within prohibited growth-hormone-releasing factors. The prohibition applies at all times. Athletes remain responsible for checking their exact product and governing rules.
What is the safest conclusion from the evidence?
Treat the consumer benefit claims as unproven and the product identity as a question that must be resolved before any evidence is interpreted. The available human data are too narrow for a reassuring safety judgement.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Claim-level recordDoes CJC-1295 raise growth hormone and IGF-1?Read the verdict, confidence, sources and scope limits.Claim-level recordDoes CJC-1295 build muscle or reduce fat?Read the verdict, confidence, sources and scope limits.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item C-015, CJC-1295: growth-hormone claims and endocrine risk was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 6 unique external sources and 11 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.